Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicingMasaki Ri(Nagoya University Hospital), Shinsuke Iida(Nagoya City University Hospital)Blood Cancer JournalJuly 20, 201210.1038/bcj.2012.26Cited by 181SaveCiteExport RISWatch citationsRelated PapersLower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy|Blood Cancer Journal|2015|49Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma|PLoS ONE|2018|28